Trial Profile
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms MOUNTAINEER
- Sponsors Seagen
- 09 Nov 2023 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Results of exploratory analysis assessing the impact of concomitant baseline genomic alterations on the clinical activity of tucatinib plus trastuzumab, presented at the 48th European Society for Medical Oncology Congress.
- 16 Oct 2023 According to Astellas media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24.